

# 2021

ONCOLOGY  
GLOBAL MEDICAL GRANTS

---

# INVESTIGATOR SPONSORED RESEARCH AND EDUCATION PROGRAMS

DISCOVERY, SUPPORT,  
AND COLLABORATION




## 2021 ONCOLOGY GLOBAL MEDICAL GRANTS

### Pfizer's Commitment to the Oncology Community

Pfizer helps to improve outcomes for patients through the provision of independent grants in support of research, education and healthcare quality improvement.

In 2020, through the Oncology Global Medical Grants program, Pfizer approved **522 projects** for investigator-sponsored research, independent medical education and quality improvement, totaling approximately **\$100 million USD**. The grants were awarded in **47 countries**, with the potential to initially impact more than **8 million patients**. The potential patient impact over time is even greater given that it is estimated that globally 1 in 5 people develop cancer in their lifetime. Together with researchers, clinicians, professional organizations, and patients, we are committed to help improve the lives of people with cancer, as well as their families and caregivers.



**NEW GRANT AWARDS IN 47  
COUNTRIES IN 2020!**

## 2021 ONCOLOGY GLOBAL MEDICAL GRANTS

### Competitive Grant Programs

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

In certain clinical areas, a more general Request for Proposal (RFP) is posted and uses an internal review process.

A general RFP describes:

- Clinical area of interest
- Approximate total budget available
- Rationale behind the need for knowledge-driven education or assessment
- Information required in the application

In 2020 GMG Oncology offered more than 32 competitive grant programs within the areas of breast cancer, lung cancer, prostate cancer, colorectal cancer, melanoma, hematology-oncology, renal cell carcinoma, and immuno-oncology.

For more information on open RFPs, please visit:

[www.pfizer.com/competitive-grants](http://www.pfizer.com/competitive-grants)



# 2021 ONCOLOGY GLOBAL MEDICAL GRANTS

## Research Grants

Pfizer supports the global healthcare community's independent research initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

## General Research Grants

General research projects can be focused on the development or refinement of specific and defined medical knowledge. This grant type is used to support research that does not include the study of a Pfizer asset, including health services research unrelated to a Pfizer asset, registry development and/or queries unrelated to a Pfizer asset, and outcomes research unrelated to a Pfizer asset. This includes observational studies, such as epidemiology studies and certain outcomes research studies where the primary focus is the scientific understanding of disease as well as other types of independent research on disease states.

## Investigator Sponsored Research

Pfizer supports Investigator Sponsored Research (ISR) projects that advance medical and scientific knowledge about our therapies. An ISR is a type of grant that supports an independent research study where the investigator or organization is the sponsor of the study and where Pfizer provides

financial and/or non-financial support for the development or refinement of specific and defined medical knowledge relating to a Pfizer asset. This global program is open to all researchers who are interested in conducting their own research. This grant is used as support for pre-clinical and clinical studies (including interventional and non-interventional), that involve a Pfizer medicine (e.g., commercial drug, investigational drug, pure compound\*).

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research/quality improvement program.

Pfizer accepts independent research grants across a variety of clinical areas. To view our ISR areas of interest, please visit: [www.pfizer.com/isr](http://www.pfizer.com/isr)

If you have any questions please email us at: [GlobalMedicalGrants@pfizer.com](mailto:GlobalMedicalGrants@pfizer.com)

Go directly to the Grant System to submit a new application or view an existing application: <https://www.cybergrants.com/pfizer/Research>



## NEW! STARTING JANUARY 1, 2021 – QUARTERLY APPLICATION AND REVIEW CYCLES

In order to provide a more efficient and transparent review process for the Oncology ISR program, we are pleased to announce the following application windows for 2021. Our commitment is to review all proposals and send out decision notifications by the notification deadlines below:

Submission Window	Notification deadline*
January 1 – March 31, 2021	May 19, 2021
April 1 – June 30, 2021	August 18, 2021
July 1 – October 8, 2021	December 1, 2021
October 9, 2021 – January 6, 2022	February 24, 2022

\* Please note that all studies involving avelumab will require 2-3 additional weeks beyond this date due to inter-company Alliance review schedules

**Important note for applicants:** Please do not wait until the submission deadline to enter your request into the online portal. Plan to apply early to allow time for clarification questions and to ensure completeness.

Qualified researchers are invited to submit investigator-sponsored research (ISR) proposals, according to the guidance and instructions found on the Pfizer ISR portal at [www.Pfizer.com/ISR](http://www.Pfizer.com/ISR). All proposals must be submitted via the ISR submission portal. An ISR proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for ISR submissions are made by the applicable Pfizer Global Review Committee. A formal notification regarding the status of your application will be sent on or before the posted notification date. Pfizer support will only be extended upon the execution of an ISR agreement. For any questions, please send an email to [GlobalMedicalGrants@pfizer.com](mailto:GlobalMedicalGrants@pfizer.com).



## 2021 ONCOLOGY GLOBAL MEDICAL GRANTS

### Oncology Assets Available for Investigator Sponsored Research

Compound Name	Compound Target
avelumab**	PD-L1
axitinib	VEGFR 1, 2, and 3
bevacizumab-bvzr*	VEGF-A
binimetinib*****	MEK
bosutinib	BCR-Abl, Src
crizotinib	c-MET, ALK, ROS1
dacomitinib	EGFR
elranatamab	BCMA-CD3
encorafenib*****	RAF
enzalutamide***	Androgen Receptor
gemtuzumab ozogamicin	CD33
inotuzumab ozogamicin	CD22
lorlatinib	ALK, ROS1
palbociclib	CDK4/6
relugolix****	GnRH
rituximab-pvvr*	CD20
sasanlimab	PD-L1
sunitinib	VEGFR1-3, PDGFR, KIT, FLT-3, RET
talazoparib	PARP
trastuzumab—qyyp*	HER2

\* biosimilar

\*\* co-developed with Merck KGaA, Darmstadt, Germany

\*\*\* co-developed with Astellas

\*\*\*\* co-developed with Myovant

\*\*\*\*\* co-developed with Pierre Fabre and Ono Pharmaceutical

## 2021 ONCOLOGY GLOBAL MEDICAL GRANTS

### Quality Improvement

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent quality improvement initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/ or scientific strategies.

For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

A quality improvement (QI) grant is a type of grant which consists of Pfizer funding to support independent projects for systematic and continuous actions that lead to measurable improvement in health care services and the health status of individuals and targeted patient groups and do not relate to a Pfizer asset.

Quality improvement considers aspects of quality such as clinical competence, outcomes and process assessment, program evaluation, quality indicators, and quality assurance using methodologically rigorous protocols with an endpoint goal of readiness for application to practice.

For more information on Quality Improvement initiatives, please visit: [www.pfizer.com/quality-improvement](http://www.pfizer.com/quality-improvement)



## 2021 ONCOLOGY GLOBAL MEDICAL GRANTS

### Independent Medical Education (IME)

Pfizer Global Medical Grants recognizes knowledge exchange as an important component of the continuing education continuum and offers support for these programs through independent medical education grants.

An independent medical education grant is a type of grant which consists of Pfizer funding for independent medical education activities or initiatives which serve to maintain, develop, or increase the knowledge, skills, and/or professional performance of a healthcare professional (e.g. continuing medical education, continuing health education, continuing education). These activities or initiatives may or may not be accredited.

### Annual Meetings

Eligible organizations can request funding to support LIVE national and regional conferences and congresses. Impacted by COVID-19 in 2020, GMG Oncology approved 66 Annual Meeting grant requests.

For more details regarding eligibility, areas of interest, and educational goals for the current year, please visit: [www.pfizer.com/independentmeded](http://www.pfizer.com/independentmeded)



### Submission Deadlines

Application Cycle*	To Submit Live Activity Must Start On or After	Decision Communicate By
Jan 1 – Feb 15	Apr 1	Mar 16
Mar 1 – Apr 15	Jul 1	Jun 1
Jun 1 – Jul 15	Oct 1	Aug 31
Sept 1 – Oct 15	Jan 1	Nov 30

\*Applications may be submitted earlier, but not later, than the relevant application cycle

### Visiting Professorships

Eligible organizations can request funding to host a medical expert to foster educational exchanges with local healthcare providers who can benefit from the expert's knowledge and on-site presence.

For more details regarding eligibility, areas of interest, and educational goals for the current year, please visit: [www.pfizer.com/independentmeded](http://www.pfizer.com/independentmeded)





